At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-blind, Placebo Controlled, Randomised, Phase IIA Pharmacodynamic 4-way Cross-over Study to Estimate the Dose Response Relationship of AZD3355 on the Number of Reflux Episodes Assessed by Impedance/pH in Patients With GERD and a Partial Response to PPI Treatment
In Brief
A Phase 2 clinical trial evaluating AZD3355 and placebo for Gastroesophageal Reflux Disease. Completed, enrolled 27 participants across 1 site.
Detailed Summary
The purpose of the study is to estimate what effect 4 different doses of AZD3355 will have on the number of reflux episodes, in patients who have GERD and still experience symptoms despite proton pump inhibitor (PPI) treatment.
Study Details
Timeline
Interventions
30 mg orally in the morning and 30 mg in the evening for 1 day
90 mg orally in the morning and 90 mg in the evening for 1 day
120 mg orally in the morning and 120 mg in the evening for 1 day
240 mg orally in the morning and 240 mg in the evening for 1 day
Placebo capsules orally in the morning and placebo capsules in the evening for 1 day